News about Market

Lupin Launches Formoflo-G for COPD Management in India

Lupin has launched Formoflo-G MDI, world's first fixed-dose triple combination of glycopyrronium, formoterol and fluticasone for moderate to severe COPD management.

Market | 06/10/2026 | By News Bureau |  118

NEC, Taiho and Partners Develop Quantum Platform for Cancer Therapy

NEC, Taiho Pharmaceutical and three Japanese research organisations launch a quantum computing project for cancer immunotherapy.

Market | 05/10/2026 | By News Bureau

Italfarmaco, JCR Sign License Deal for Hunter Syndrome Therapy

JCR Pharmaceuticals and Italfarmaco expand their rare disease collaboration with a global license agreement for JR-141.

Market | 05/10/2026 | By News Bureau

NICE Recommends Tryngolza for Familial Chylomicronaemia Syndrome

National Institute for Health and Care Excellence issues final draft guidance recommending Tryngolza as a treatment option for eligible adults with familial chylomicronaemia syndrome.

Market | 03/10/2026 | By News Bureau

Samsung Bioepis and Teva Expand Biosimilar Partnership

Samsung Bioepis and Teva expand their strategic partnership to develop and commercialise up to 6 biosimilar candidates across the US, Europe and Canada.

Market | 03/10/2026 | By News Bureau

AbbVie and Valkai Partner to Advance AI in Clinical Development

AbbVie has partnered with Valkai to expand AI across clinical development, advancing drug development, scientific innovation, operational efficiency and patient outcomes.

Market | 03/10/2026 | By News Bureau |  106

MrMed Reports 123 Percent Revenue Growth to INR 74.3 Crore in FY26

MrMed records INR 74.3 crore revenue and closed FY26 EBITDA positive, with most revenue coming from non-metro markets.

Market | 01/10/2026 | By News Bureau |  121

Acrotech Biopharma Launches Adquey for Atopic Dermatitis in US

Acrotech Biopharma launches Adquey ointment in the US for the topical treatment of mild-to-moderate atopic dermatitis.

Market | 01/10/2026 | By News Bureau

AstraZeneca and Summit Therapeutics Partner on ADC Cancer Strategy

AstraZeneca has announced strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer.

Market | 01/10/2026 | By News Bureau

Chugai Licenses RAF-MEK Molecular Glue SPYK04 to InxMed

Chugai Pharmaceutical grants InxMed an exclusive worldwide licence for SPYK04, a RAF-MEK molecular glue being developed for solid tumours.

Market | 30/09/2026 | By News Bureau